Previous close | 0.5113 |
Open | 0.5000 |
Bid | 0.0000 x 1800 |
Ask | 0.0000 x 1200 |
Day's range | 0.4900 - 0.5400 |
52-week range | 0.4010 - 2.3400 |
Volume | |
Avg. volume | 700,856 |
Market cap | 47.977M |
Beta (5Y monthly) | 0.87 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.7200 |
Earnings date | 27 Mar 2023 - 31 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 3.56 |
NEW YORK, January 17, 2023--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or "Lucid Diagnostics"), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc. ("Veris"), a private digital health company focused on enhanced personalized cancer care, today provided a
NEW YORK, January 11, 2023--Companies will present refinements to their business strategy as each continue to the benefit patients in need and create value for shareholders.
NEW YORK, December 22, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has entered into a license option and joint research and development agreement with Novosound Ltd. ("Novosound"), a venture-backed technology company based in Glasgow, Scotland, to explore applying Novosound’s proprietary flexible thin-film ultrasound technology in me